There are 1.2 million hiv positive people in the USA. Ccr5 tropism hiv is about 70% of that, 840,000 total. If leronlimab treats just 10% of that population, at about $40k a year we are at $3.3 billion a year in revenue. That is only 10% of the market in the USA. I don’t think that is small.